scholarly journals Effects of Vitamin E on Fasting and Postprandial Oxidative Stress, Inflammatory Markers, Glucose Status, Insulin Resistance, Blood Pressure and Pulse Rate in Type-2 Diabetic Patients: A Randomized Clinical Trial

2015 ◽  
Vol 4 (3) ◽  
pp. 67-74
Author(s):  
Najmeh Hejazi ◽  
Mohammad Hossein Dabbaghmanesh ◽  
Zohreh Mazloom ◽  
Arash Dashtabi
Keyword(s):  
Oxidative Stress ◽  
Blood Pressure ◽  
Vitamin E ◽  
Pulse Rate ◽  
Diabetic Patients ◽  
Short Term ◽  
Type 2 Diabetic Patients ◽  
Significant Difference ◽  
Type 2 Diabetic

Background: Atherosclerosis is one of the prevalent complications in diabetic patients. Increased free radical levels in diabetes activate stress-sensitive signaling pathway, resulting in this outcome. This study examines the effect of short-term supplementation of vitamin E on different biochemical markers in type 2 diabetic patients to prevent from atherosclerosis. Materials and Methods: In this single-blind placebo controlled trial, 30 type 2 diabetic patients were randomly divided into two groups of study to receive vitamin E (400IU) or identical placebo capsules daily for 6 weeks. Serum level of lipoproteins, glucose, insulin, malondialdehyde (MDA), interleukin-6 (IL-6), high-sensitivity C-reactive protein (hs CRP), pulse rate and blood pressure were measured in fasting and postprandial (after a fatty meal) states before and after six weeks of supplementation. Results: There was not any significant difference in fasting and postprandial lipid profile (Triglyceride, HDL-, LDL- and total Cholesterol), glucose, insulin and HOMA-IR after six weeks of intervention between the two groups. However, results of our study showed a significant decrease in fasting and postprandial MDA levels and postprandial pulse rate and a significant increase in fasting IL-6 in vitamin E group compared to the controls after supplementation. There were no significant differences between the groups in other markers. Conclusion: This study suggests that short term supplementation of vitamin E can reduce oxidative stress in fasting and postprandial states in type 2 diabetic patients and may prevent diabetic complications; in addition, increment of IL-6 after supplementation may play a role in attenuating Type 2 diabetes by anti-inflammatory effects.[GMJ. 2015;4(3):67-74]

scholarly journals Medium- and Short-Term Interventions with Ma-Pi 2 Macrobiotic Diet in Type 2 Diabetic Adults of Bauta, Havana

2012 ◽  
Vol 2012 ◽  
pp. 1-10 ◽  
Author(s):  
Carmen Porrata-Maury ◽  
Manuel Hernández-Triana ◽  
Eduardo Rodríguez-Sotero ◽  
Raúl Vilá-Dacosta-Calheiros ◽  
Héctor Hernández-Hernández ◽  
...  
Keyword(s):  
Blood Pressure ◽  
Dietary Intervention ◽  
Diabetic Patients ◽  
Short Term ◽  
Type 2 Diabetic Patients ◽  
Biochemical Indicators ◽  
Serum Biochemical ◽  
Macrobiotic Diet ◽  
Type 2 Diabetic

Background.In Cuba, the Ma-Pi 2 macrobiotic diet has shown positive results in 6-month assays with type 2 diabetic patients. The objective of this study was to assess the influence of this diet at short and medium terms.Methods.Sixty-five type 2 diabetic volunteers were included for dietary intervention, institutionally based for 21 days and followed later at home, until completing 3 months. 54 of them stayed until assay end. Before intervention, and after both assay periods, they were submitted to anthropometric records, body composition analyses and measurements of serum biochemical indicators, glycemic profile in capillary blood, blood pressure, and medication consumption; food intake was evaluated by the 3-day dietary recall.Results.During the intervention, the energy intake was 200 kcal higher at instance of more complex carbohydrates and dietary fiber and despite less fat and protein. Blood pressure and serum biochemical indicators decreased significantly in both periods; the safety nutritional indicators (hemoglobin, serum total proteins, and albumin) showed no variations. The global cardiovascular risk decreased and insulin consumption dropped by 46% and 64%, in both periods, respectively.Conclusions.The Ma-Pi 2 macrobiotic diet was a successful therapy at short term and after 3-month home-based intervention, for type 2 diabetics.

scholarly journals Raised Arterial Pressure and Microalbuminuria in Type 2 Diabetic Subjects with Familial Hypertension

2016 ◽  
Vol 4 (1) ◽  
pp. 14-18
Author(s):  
Md Anisur Rahman ◽  
Md Mostarshid Billah ◽  
Palash Mitra ◽  
Md Emtiaz Hossan ◽  
Md Jakir Hossain ◽  
...  
Keyword(s):  
Blood Pressure ◽  
Arterial Pressure ◽  
Diabetic Patients ◽  
Type 2 Diabetic Patients ◽  
Familial Predisposition ◽  
Significant Difference ◽  
History Of ◽  
Family History Of Hypertension ◽  
Type 2 Diabetic

Background and Aims : Microalbuminuria is claimed to be an early marker of nephropathy in type 2 diabetes.The raised arterial pressure is an important factor in the progression of diabetic nephropathy. There is a significant correlation between blood pressure and the progression of albuminuria in both type 1 and type 2 diabetes. This study in Bangladeshi type 2 diabetic patients was to evaluate whether microalbuminuria and raised arterial pressure are influenced by familial predisposition to hypertension.Methods : Sixty three newly diagnosed Bangladeshi type 2 diabetic patients were investigated. The diabetic subjects were divided into two groups as diabetes with family history of hypertension (n=37) and diabetes without family history of hypertension (n=26). Diabetic subjects were further divided into normotensive (n= 46) and hypertensive (n= 17); diabetic normoalbuminuric (n 44) and diabetic microalbuminuric (n 19) subgroups. Serum glucose was measured by glucose-oxidase; blood urea, serum creatinine and urinary creatinine by enzymatic-colorimetric method and urinary albumin by immunoturbidimetry method.Results : systolic blood pressure (SBP), diastolic blood pressure (DBP) and microalbuminuria were significantly elevated in diabetic subjects with familial predisposition to hypertension when compared to diabetic subjects without familial predisposition to hypertension [SBP (127±16 vs 110±14) mmHg P= 0.001; DBP (81±9 vs 72±11) mmHg P= 0.001; Microalbuminuria 2.23(0.28-9.43) vs 1.52(.29-3.91) mg/mmol p<0.03]. When diabetic normotensive subjects were compared with diabetic hypertensive subjects for microalbuminuria, no significant difference was found among themselves [median (range) 1.67(0.17-8.62) vs 1.70(.28-9.43) mg/mmol p = NS]. Comparison of blood pressure was found no significant difference between diabetic normoalbuminuric and diabetic microalbuminuric subjects [systolic blood pressure (117±17 vs 125±17) mmHg p= NS ; diastolic blood pressure (76±11 vs 82±10) mmHg p= NS ].Conclusion : Microalbuminuria, a marker of early diabetic nephropathy and raised arterial pressure, a progression factor of nephropathy are more influenced by familial predisposition to hypertension in diabetic population irrespective of presence or absence of microalbuminuria and hypertension.Bangladesh Crit Care J March 2016; 4 (1): 14-18

scholarly journals Leukocyte Lipid Peroxidation, Superoxide Dismutase and Catalase Activities of Type 2 Diabetic Patients with Retinopathy

2005 ◽  
Vol 48 (1) ◽  
pp. 35-38 ◽  
Author(s):  
Naciye Kurtul ◽  
Ebubekir Bakan ◽  
Hülya Aksoy ◽  
Orhan Baykal
Keyword(s):  
Oxidative Stress ◽  
Lipid Peroxidation ◽  
Superoxide Dismutase ◽  
Diabetic Retinopathy ◽  
Diabetic Patients ◽  
Type 2 Diabetic Patients ◽  
Significant Difference ◽  
Type 2 Diabetic ◽  
Type 2 Diabetic Retinopathy

Increased oxidative stress might play an important role in the initiation and progression of diabetic complications. The present study has been undertaken to investigate whether there is any relationship between retinopathy degree and leukocyte superoxide dismutase (SOD) and catalase (CAT) activities and lipid peroxidation (LPO) in diabetic individuals with type 2 diabetic retinopathy. Patients were groupped with respect to the degree of retinopathy. Leukocyte malondialdehyde (MDA) levels, and SOD and CAT activities were measured in patients with type 2 diabetes mellitus (n=41) and nondiabetic healthy controls (n=23). Leukocyte LPO of the type 2 diabetic patients with retinopathy was significantly increased (p< 0.001), whereas SOD and CAT activities were decreased (p<0.001 and p<0.001, respectively) compared to those of controls. MDA concentrations rose while SOD and CAT activities fell with increasing severity of diabetic retinopathy, altough there was no significant difference in comprasion of the parameters mentioned above between the diabetic patients with and without retinopathy. Our results show that leukocytes in patients with type 2 diabetic retinopathy are affected by oxidative stress which might be contribute to pathogenesis of diabetic retinopathy. Prospective studies are needed to evaulate the relationship between the leukocyte antioxidants status and DR.

scholarly journals Short-term renoprotective effect of SGLT-2 inhibitor for renal function and albuminuria in type 2 diabetes

2020 ◽  
Author(s):  
Mitsunobu Kubota ◽  
Eri SHiroyama ◽  
Kanako Tanaka ◽  
Yoko Yoshii
Keyword(s):  
Blood Pressure ◽  
Body Weight ◽  
Diabetic Patients ◽  
Protective Effects ◽  
Renal Protection ◽  
Short Term ◽  
Type 2 Diabetic Patients ◽  
Before And After ◽  
Type 2 Diabetic

Abstract Background Progression of diabetic nephropathy in type 2 diabetic patients is a factor that determines the prognosis of life. Empagliflozin and canagliflozin, two oral diabetic SGLT-2 inhibitors, have shown improved renal outcomes in type 2 diabetic patients with chronic kidney disease in a large clinical study. These results suggest that SGLT-2 inhibitors could be used not only for hypoglycemic effects, but also for renal protective effects in patients with type 2 diabetes. It is not fully understood in which contexts the use of SGLT-2 inhibitors is likely to exert its renal protective effects. The purpose of this study was to clarify the profiles of patients in whom SGLT-2 inhibitors are more likely to exert a renal protective effect in clinical practice. We examined renal function and urinary albumin changes in short-term use of SGLT-2 inhibitors by patient background. Methods We retrospectively analyzed the chart information of sixty-three type 2 diabetic patients (33 males, 30 females, average age 53.0 ± 13.0 years) who were given usual doses of a SGLT-2 inhibitor. We investigated changes in body weight, blood pressure, glucose metabolism index, lipid metabolism index, estimated glomerular filtration rate (eGFR) and albuminuria (urinary albumin-to-creatinine ratio, UACR) three months before and after administration of a SGLT-2 inhibitor. Results Three months after administration of an SGLT-2 inhibitor, there were improvements in glucose tolerance, weight loss, blood pressure, and lipid indices. In all cases, there was no significant change in eGFR, but UACR decreased significantly. UACR decreased regardless of Angiotensin II Receptor Blocker medication and significantly decreased in the nephropathy stage 2 and 3 groups. UACR decreased only in the group in which blood pressure, body weight, and HbA1c decreased before and after administration of the SGLT-2 inhibitor. Conclusions Our study shows that SGLT-2 inhibitors are independent of renin-angiotensin system (RAS) inhibitors, and in addition to direct renal protection, the comprehensive effects of SGLT-2 inhibitors, which lower body weight, blood pressure, and blood glucose, are also important for their renal protection effects.

scholarly journals Short-term renoprotective effect of SGLT-2 inhibitor for renal function and albuminuria in type 2 diabetes: a retrospective study

2020 ◽  
Author(s):  
Mitsunobu Kubota ◽  
Eri Shiroyama ◽  
Kanako Tanaka ◽  
Yoko Yoshii
Keyword(s):  
Blood Pressure ◽  
Body Weight ◽  
Diabetic Patients ◽  
Protective Effects ◽  
Renal Protection ◽  
Short Term ◽  
Type 2 Diabetic Patients ◽  
Before And After ◽  
Type 2 Diabetic

Abstract Background Progression of diabetic nephropathy in type 2 diabetic patients is a factor that determines the prognosis of life. Empagliflozin and canagliflozin, two oral diabetic SGLT-2 inhibitors, have shown improved renal outcomes in type 2 diabetic patients with chronic kidney disease in a large clinical study. These results suggest that SGLT-2 inhibitors could be used not only for hypoglycemic effects, but also for renal protective effects in patients with type 2 diabetes. It is not fully understood in which contexts the use of SGLT-2 inhibitors is likely to exert its renal protective effects. The purpose of this study was to clarify the profiles of patients in whom SGLT-2 inhibitors are more likely to exert a renal protective effect in clinical practice. We examined renal function and urinary albumin changes in short-term use of SGLT-2 inhibitors by patient background. Methods We retrospectively analyzed the medical record information of sixty-three type 2 diabetic patients (33 males, 30 females, average age 53.0 ± 13.0 years) who were given usual doses of a SGLT-2 inhibitor. We investigated changes in body weight, blood pressure, glucose metabolism index, lipid metabolism index, estimated glomerular filtration rate (eGFR) and albuminuria (urinary albumin-to-creatinine ratio, UACR) three months before and after administration of a SGLT-2 inhibitor. Results Three months after administration of an SGLT-2 inhibitor, there were improvements in glucose tolerance, weight loss, blood pressure, and lipid indices. In all cases, there was no significant change in eGFR, but UACR decreased significantly. UACR decreased regardless of Angiotensin II Receptor Blocker medication and significantly decreased in nephropathy patients with microalbuminuria or overt albuminuria. UACR decreased only in the group in which blood pressure, body weight, and hemoglobin A1c decreased before and after administration of the SGLT-2 inhibitor. Conclusions Our study shows that the renoprotective effects of SGLT-2 inhibitors are more likely to be exerted in diabetic nephropathy patients who have advanced to at least microalbuminuria stage, and in addition to direct renal protection, the comprehensive effects of SGLT-2 inhibitors, which lower body weight, blood pressure, and blood glucose, are also important for their renal protection effects.

scholarly journals Short-term Renoprotective Effect of SGLT-2 Inhibitor for Renal Function and Albuminuria in Type 2 Diabetes: A Retrospective Study

2020 ◽  
Author(s):  
Mitsunobu Kubota ◽  
Eri Shiroyama ◽  
Kanako Tanaka ◽  
Yoko Yoshii
Keyword(s):  
Blood Pressure ◽  
Body Weight ◽  
Diabetic Patients ◽  
Protective Effects ◽  
Renal Protection ◽  
Short Term ◽  
Type 2 Diabetic Patients ◽  
Before And After ◽  
Type 2 Diabetic

Abstract Background Progression of diabetic nephropathy in type 2 diabetic patients is a factor that determines the prognosis of life. Empagliflozin and canagliflozin, two oral diabetic SGLT-2 inhibitors, have shown improved renal outcomes in type 2 diabetic patients with chronic kidney disease in a large clinical study. These results suggest that SGLT-2 inhibitors could be used not only for hypoglycemic effects, but also for renal protective effects in patients with type 2 diabetes. It is not fully understood in which contexts the use of SGLT-2 inhibitors is likely to exert its renal protective effects. The purpose of this study was to clarify the profiles of patients in whom SGLT-2 inhibitors are more likely to exert a renal protective effect in clinical practice. We examined renal function and urinary albumin changes in short-term use of SGLT-2 inhibitors by patient background. Methods We retrospectively analyzed the medical record information of sixty-three type 2 diabetic patients (33 males, 30 females, average age 53.0 ± 13.0 years) who were given usual doses of a SGLT-2 inhibitor. We investigated changes in body weight, blood pressure, glucose metabolism index, lipid metabolism index, estimated glomerular filtration rate (eGFR) and albuminuria (urinary albumin-to-creatinine ratio, UACR) three months before and after administration of a SGLT-2 inhibitor. Results Three months after administration of an SGLT-2 inhibitor, there were improvements in glucose tolerance, weight loss, blood pressure, and lipid indices. In all cases, there was no significant change in eGFR, but UACR decreased significantly. UACR decreased regardless of Angiotensin II Receptor Blocker medication and significantly decreased in nephropathy patients with microalbuminuria or overt albuminuria. UACR decreased only in the group in which blood pressure, body weight, and HbA1c decreased before and after administration of the SGLT-2 inhibitor. Conclusions Our study shows that the renoprotective effects of SGLT-2 inhibitors are more likely to be exerted in diabetic nephropathy patients who have advanced to at least microalbuminuria stage, and in addition to direct renal protection, the comprehensive effects of SGLT-2 inhibitors, which lower body weight, blood pressure, and blood glucose, are also important for their renal protection effects.

Sign in / Sign up

Export Citation Format

Share Document